Product Pipeline

Drug Candidate

Indication

Commercial Right

US

Partners

Regulatory Designation

ASC-930

GVHD

Global

Cell Therapy

Orphan drug designation

ASC-618

Hemophilia A

Global

Gene Therapy

Orphan drug designation

ASC-518

Hemophilia A

Partnered

Gene Editing

ASC-519

Hemophilia B

Partnered

Gene Editing

ASC-520

β-Thalassemia

Partnered

Gene Editing

abc

Leading Products

Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies. Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.

Our Pipeline

Drug Candidate

Indication

Commercial Right

US

Partners

Regulatory Designation

ASC-930

GHVD

Global

Cell Therapy

Orphan drug designation

ASC-618

Hemophilia A

Global

Gene Therapy

Orphan drug designation

ASC-518

Hemophilia A

Partnered

Gene Editing

ASC-519

Hemophilia B

Partnered

Gene Editing

ASC-520

β-Thalassemia

Partnered

Gene Editing

abc

Leading Products

Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies. Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.